Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 9/2018

01-09-2018 | Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer

Authors: Skyler B. Johnson, James B. Yu

Published in: Current Oncology Reports | Issue 9/2018

Login to get access

Abstract

Purpose of Review

Here, we will review and summarize the current status and emerging data supporting the use of trimodality therapy as an alternative to cystectomy for patients with muscle-invasive bladder cancer.

Recent Findings

There are no randomized-controlled data comparing radical cystectomy with bladder preserving trimodality therapy available for comparison. However, observational data suggests acceptable bladder preservation and functional outcomes in patients receiving bladder preserving trimodality therapy as well as similar oncologic outcomes in select patients compared to radical cystectomy. Future trials are focusing on new techniques and novel therapeutics in patients with bladder cancer.

Summary

Bladder preserving trimodality therapy results in satisfactory quality of life and comparable disease outcomes for select patients with muscle-invasive urothelial carcinoma of the bladder compared to cystectomy.
Literature
1.
2.
3.
Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol 2014;66(2):361–70.
4.
Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164–76.PubMedCrossRef
5.
Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55(1):177–86.PubMedCrossRef
6.
Zakaria AS, Santos F, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: a population-based analysis during the years 2000-2009. Can Urol Assoc J= J Assoc Urol Can. 2014;8(7–8):259–67.CrossRef
7.
Group EBCTC. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef
8.
Wolf G, Hong K, Fisher S. The Department of Veterans Affairs Laryngeal Cancer Study Group: induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.PubMedCrossRef
9.
Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.PubMedPubMedCentralCrossRef
10.
Sischy B, Doggett RS, Krall JM, Taylor DG, Sause WT, Lipsett J, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on radiation therapy oncology group study no. 8314. JNCI: J Natl Cancer Inst. 1989;81(11):850–7.PubMedCrossRef
11.
Shipley W, Winter K, Kaufman D, Lee W, Heney N, Tester W, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576–83.PubMedCrossRef
12.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.PubMedCrossRef
13.
Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Jr D, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71.PubMedCrossRef
14.
Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11.PubMedCrossRef
15.
Onozawa M, Miyanaga N, Hinotsu S, Miyazaki J, Oikawa T, Kimura T, et al. Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer. Jpn J Clin Oncol. 2012;42(9):825–30.PubMedCrossRef
16.
Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu C-L, Wu S, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol. 2017;72(1):54–60.PubMedCrossRef
17.
Shipley WU, Rose M, Perrone TL, Mannix CM, Heney NM, Prout GR Jr. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985;134(4):679–83.PubMedCrossRef
18.
Gospodarowicz M, Hawkins N, Rawlings G, Connolly J, Jewett M, Thomas G, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142(6):1448–1453; discussion 53–4.
19.
Koga F, Numao N, Saito K, Masuda H, Fujii Y, Kawakami S, et al., editors. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier.
20.
Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37.PubMedCrossRef
21.
Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57.PubMedCrossRef
22.
Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15(3):1022–9.PubMedCrossRef
23.
Shipley W, Kaufman D, Eea Z, Heney N, Lane S, Thakral H, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60(1):62–7.PubMedCrossRef
24.
Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013;111(8):1215–21.PubMedCrossRef
25.
Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, et al. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013;87(2):261–9.PubMedPubMedCentralCrossRef
26.
Zapatero A, De Vidales CM, Arellano R, Ibañez Y, Bocardo G, Perez M, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012;80(5):1056–62.PubMedCrossRef
27.
Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debré B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63(1):73–7.PubMedCrossRef
28.
Lin C-C, Hsu C-H, Cheng JC, Huang C-Y, Tsai Y-C, Hsu F-M, et al. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2009;75(2):442–8.PubMedCrossRef
29.
Coppin C, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14(11):2901–7.PubMedCrossRef
30.
Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. BJU Int. 1997;80(1):44–9.CrossRef
31.
Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14(1):119–26.PubMedCrossRef
32.
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665–72.PubMedCrossRef
33.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7.PubMedCrossRef
34.
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu C-L, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863–72.PubMedPubMedCentralCrossRef
35.
Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-sarraf M, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2001;165(1):56–61.PubMedCrossRef
36.
Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–73.PubMedCrossRef
37.
Dunst J, Sauer R, Schrott KM, Kühn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994;30(2):261–6.PubMedCrossRef
38.
Shipley WU, Prout GR, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258(7):931–5.PubMedCrossRef
39.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471–6.PubMedCrossRef
40.
Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol. 2004;172(4):1276–80.PubMedCrossRef
41.
Hussain S, Stocken D, Peake D, Glaholm J, Zarkar A, Wallace D, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90(11):2106–11.PubMedPubMedCentralCrossRef
42.
Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003;57(5):1310–6.PubMedCrossRef
43.
Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29(6):733–8.PubMedCrossRef
44.
Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74(2):511–7.PubMedCrossRef
45.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15(10):1240–67.CrossRef
46.
Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30(2):267–77.PubMedCrossRef
47.
Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2008;54(1):126–32.PubMedCrossRef
48.
Solsona E, Climent MA, Iborra I, Collado A, Rubio J, Ricós JV, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009;55(4):911–21.PubMedCrossRef
49.
Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11(11):2150–7.PubMedCrossRef
50.
Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75(1):34–43.PubMedCrossRef
51.
Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node–negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–e62.PubMedCrossRef
52.
Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27(25):4055–61.PubMedPubMedCentralCrossRef
53.
McDonald F, Hall E, James N, Huddart R. 2043 defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial. Eur J Cancer Suppl. 2009;7(2):163–4.CrossRef
54.
Chauvet B, Brewer Y, Felix-Faure C, Davin J-L, Choquenet C, Reboul F. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol. 1996;156(4):1258–62.PubMedCrossRef
55.
Grossman HB, Natale RB, Tangen CM, Speights V, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRef
56.
Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys. 2010;77(1):119–24.PubMedCrossRef
57.
• Pietzak EJ, Sterling ME, Smith ZL, Malkowicz SB, Guzzo TJ. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. Urology. 2015;85(4):869–75. This is a recent retrospective study that compared BPTT eligible versus ineligible patients who underwent cystectomy. Of those who had cystectomy but were BPTT eligible, 24% had occult positive nodes and 36% had pT3 or pT4 tumors. The 2-year OS was 76.7 vs. 57.1% for BPTT eligible vs ineligible patients who underwent cystectomy. PubMedCrossRef
58.
Huddart R, Birtle A, Lewis R, Bahl A, Falconer A, Maynard L, Hall E Results of the SPARE feasibility study—selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder (CRUK/07/011). Int J Radiat Oncol*Biol*Phys 2012;84(3, Supplement):S119-SS20.
59.
Huddart RA, Hall E, Lewis R, Birtle A. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int. 2010;106(6):753–5.PubMedCrossRef
60.
• Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, Kaushik D Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2017;97(5):1002–1020. This is a recent large meta-analysis of 9554 patients from 8 studies that compared cystectomy to BPTT. There was no difference in disease-specific, nor OS at 5 and 10 years and no difference in progression-free survival at 10 years between cystectomy and BPTT. Cystectomy was associated with higher rates of early major complications and rates of minor complications were similar between groups.
61.
Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170(5):1772–6.PubMedCrossRef
62.
Lagrange J-L, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero J-M, Joly F, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys. 2011;79(1):172–8.PubMedCrossRef
63.
Gakis G, Fahmy O. Systematic review and meta-analysis on the impact of hexaminolevulinate-versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer. 2016;2(3):293–300.PubMedPubMedCentralCrossRef
64.
Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non–muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54.PubMedCrossRef
65.
Michaelson MD, Hu C, Pham HT, Dahl DM, Wu C-L, Whittington RM, et al. The initial report of RTOG 0524: phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2014.
66.
67.
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–5.PubMedCrossRef
68.
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–25.PubMedPubMedCentralCrossRef
Metadata
Title
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
Authors
Skyler B. Johnson
James B. Yu
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Oncology Reports / Issue 9/2018
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-018-0711-0

Other articles of this Issue 9/2018

Current Oncology Reports 9/2018 Go to the issue

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks

Lung Cancer (H Borghaei, Section Editor)

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Pediatric Oncology (G Tian, Section Editor)

Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors

Gastrointestinal Cancers (J Meyer, Section Editor)

Endoscopic Treatment of Early-Stage Esophageal Cancer

Gastrointestinal Cancers (J Meyer, Section Editor)

Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies

Pediatric Oncology (G Tian, Section Editor)

Adoptive Cell Therapy in Treating Pediatric Solid Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits